Do checkpoint inhibitors compromise the cancer patients' immunity and increase the vulnerability to COVID-19 infection?
Identifieur interne : 001118 ( Main/Exploration ); précédent : 001117; suivant : 001119Do checkpoint inhibitors compromise the cancer patients' immunity and increase the vulnerability to COVID-19 infection?
Auteurs : Joseph Kattan [Liban] ; Clarisse Kattan [Liban] ; Tarek Assi [Liban]Source :
- Immunotherapy [ 1750-7448 ] ; 2020.
Descripteurs français
- KwdFr :
- Antinéoplasiques immunologiques (effets indésirables), Humains (MeSH), Infections à coronavirus (complications), Infections à coronavirus (physiopathologie), Pandémies (MeSH), Pneumopathie virale (complications), Pneumopathie virale (physiopathologie), Points de contrôle du cycle cellulaire (effets des médicaments et des substances chimiques), Tumeurs (traitement médicamenteux), Évolution de la maladie (MeSH).
- MESH :
- effets des médicaments et des substances chimiques : Points de contrôle du cycle cellulaire.
- effets indésirables : Antinéoplasiques immunologiques, Infections à coronavirus, Pneumopathie virale.
- physiopathologie : Infections à coronavirus, Pneumopathie virale.
- traitement médicamenteux : Tumeurs.
- Humains, Pandémies, Évolution de la maladie.
English descriptors
- KwdEn :
- Antineoplastic Agents, Immunological (adverse effects), Cell Cycle Checkpoints (drug effects), Coronavirus Infections (complications), Coronavirus Infections (physiopathology), Disease Progression (MeSH), Humans (MeSH), Neoplasms (drug therapy), Pandemics (MeSH), Pneumonia, Viral (complications), Pneumonia, Viral (physiopathology).
- MESH :
- chemical , adverse effects : Antineoplastic Agents, Immunological.
- complications : Coronavirus Infections, Pneumonia, Viral.
- drug effects : Cell Cycle Checkpoints.
- drug therapy : Neoplasms.
- physiopathology : Coronavirus Infections, Pneumonia, Viral.
- Disease Progression, Humans, Pandemics.
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) has been declared a pandemic by the WHO that claimed the lives of thousands of people within a few months. Cancer patients represent a vulnerable population due to the acquired immunodeficiency associated with anti-cancer therapy. Immune checkpoint inhibitors have largely impacted the prognosis of a multitude of malignancies with significant improvement in survival outcomes and a different, tolerable toxicity profile. In this paper, we assess the safety of ICI administration in cancer patients during the coronavirus pandemic in order to guide the usage of these highly efficacious agents.
DOI: 10.2217/imt-2020-0077
PubMed: 32290754
PubMed Central: PMC7161588
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Do checkpoint inhibitors compromise the cancer patients' immunity and increase the vulnerability to COVID-19 infection?</title><author><name sortKey="Kattan, Joseph" sort="Kattan, Joseph" uniqKey="Kattan J" first="Joseph" last="Kattan">Joseph Kattan</name><affiliation wicri:level="1"><nlm:affiliation>Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.</nlm:affiliation><country xml:lang="fr">Liban</country><wicri:regionArea>Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut</wicri:regionArea><wicri:noRegion>Beirut</wicri:noRegion></affiliation></author><author><name sortKey="Kattan, Clarisse" sort="Kattan, Clarisse" uniqKey="Kattan C" first="Clarisse" last="Kattan">Clarisse Kattan</name><affiliation wicri:level="1"><nlm:affiliation>Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.</nlm:affiliation><country xml:lang="fr">Liban</country><wicri:regionArea>Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut</wicri:regionArea><wicri:noRegion>Beirut</wicri:noRegion></affiliation></author><author><name sortKey="Assi, Tarek" sort="Assi, Tarek" uniqKey="Assi T" first="Tarek" last="Assi">Tarek Assi</name><affiliation wicri:level="1"><nlm:affiliation>Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.</nlm:affiliation><country xml:lang="fr">Liban</country><wicri:regionArea>Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut</wicri:regionArea><wicri:noRegion>Beirut</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32290754</idno><idno type="pmid">32290754</idno><idno type="doi">10.2217/imt-2020-0077</idno><idno type="pmc">PMC7161588</idno><idno type="wicri:Area/Main/Corpus">001731</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001731</idno><idno type="wicri:Area/Main/Curation">001731</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001731</idno><idno type="wicri:Area/Main/Exploration">001731</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Do checkpoint inhibitors compromise the cancer patients' immunity and increase the vulnerability to COVID-19 infection?</title><author><name sortKey="Kattan, Joseph" sort="Kattan, Joseph" uniqKey="Kattan J" first="Joseph" last="Kattan">Joseph Kattan</name><affiliation wicri:level="1"><nlm:affiliation>Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.</nlm:affiliation><country xml:lang="fr">Liban</country><wicri:regionArea>Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut</wicri:regionArea><wicri:noRegion>Beirut</wicri:noRegion></affiliation></author><author><name sortKey="Kattan, Clarisse" sort="Kattan, Clarisse" uniqKey="Kattan C" first="Clarisse" last="Kattan">Clarisse Kattan</name><affiliation wicri:level="1"><nlm:affiliation>Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.</nlm:affiliation><country xml:lang="fr">Liban</country><wicri:regionArea>Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut</wicri:regionArea><wicri:noRegion>Beirut</wicri:noRegion></affiliation></author><author><name sortKey="Assi, Tarek" sort="Assi, Tarek" uniqKey="Assi T" first="Tarek" last="Assi">Tarek Assi</name><affiliation wicri:level="1"><nlm:affiliation>Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.</nlm:affiliation><country xml:lang="fr">Liban</country><wicri:regionArea>Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut</wicri:regionArea><wicri:noRegion>Beirut</wicri:noRegion></affiliation></author></analytic><series><title level="j">Immunotherapy</title><idno type="eISSN">1750-7448</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic Agents, Immunological (adverse effects)</term><term>Cell Cycle Checkpoints (drug effects)</term><term>Coronavirus Infections (complications)</term><term>Coronavirus Infections (physiopathology)</term><term>Disease Progression (MeSH)</term><term>Humans (MeSH)</term><term>Neoplasms (drug therapy)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (complications)</term><term>Pneumonia, Viral (physiopathology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antinéoplasiques immunologiques (effets indésirables)</term><term>Humains (MeSH)</term><term>Infections à coronavirus (complications)</term><term>Infections à coronavirus (physiopathologie)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (complications)</term><term>Pneumopathie virale (physiopathologie)</term><term>Points de contrôle du cycle cellulaire (effets des médicaments et des substances chimiques)</term><term>Tumeurs (traitement médicamenteux)</term><term>Évolution de la maladie (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Agents, Immunological</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Cell Cycle Checkpoints</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Points de contrôle du cycle cellulaire</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antinéoplasiques immunologiques</term><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Disease Progression</term><term>Humans</term><term>Pandemics</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Pandémies</term><term>Évolution de la maladie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) has been declared a pandemic by the WHO that claimed the lives of thousands of people within a few months. Cancer patients represent a vulnerable population due to the acquired immunodeficiency associated with anti-cancer therapy. Immune checkpoint inhibitors have largely impacted the prognosis of a multitude of malignancies with significant improvement in survival outcomes and a different, tolerable toxicity profile. In this paper, we assess the safety of ICI administration in cancer patients during the coronavirus pandemic in order to guide the usage of these highly efficacious agents.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32290754</PMID><DateCompleted><Year>2020</Year><Month>05</Month><Day>06</Day></DateCompleted><DateRevised><Year>2020</Year><Month>05</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1750-7448</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>04</Month></PubDate></JournalIssue><Title>Immunotherapy</Title><ISOAbbreviation>Immunotherapy</ISOAbbreviation></Journal><ArticleTitle>Do checkpoint inhibitors compromise the cancer patients' immunity and increase the vulnerability to COVID-19 infection?</ArticleTitle><Pagination><MedlinePgn>351-354</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2217/imt-2020-0077</ELocationID><Abstract><AbstractText>The severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) has been declared a pandemic by the WHO that claimed the lives of thousands of people within a few months. Cancer patients represent a vulnerable population due to the acquired immunodeficiency associated with anti-cancer therapy. Immune checkpoint inhibitors have largely impacted the prognosis of a multitude of malignancies with significant improvement in survival outcomes and a different, tolerable toxicity profile. In this paper, we assess the safety of ICI administration in cancer patients during the coronavirus pandemic in order to guide the usage of these highly efficacious agents.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kattan</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kattan</LastName><ForeName>Clarisse</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Assi</LastName><ForeName>Tarek</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Immunotherapy</MedlineTA><NlmUniqueID>101485158</NlmUniqueID><ISSNLinking>1750-743X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000074322">Antineoplastic Agents, Immunological</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000074322" MajorTopicYN="N">Antineoplastic Agents, Immunological</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059447" MajorTopicYN="N">Cell Cycle Checkpoints</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID-19</Keyword><Keyword MajorTopicYN="Y">cancer</Keyword><Keyword MajorTopicYN="Y">checkpoints inhibitors</Keyword><Keyword MajorTopicYN="Y">coronavirus</Keyword><Keyword MajorTopicYN="Y">immune therapy</Keyword><Keyword MajorTopicYN="Y">immunosuppression</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>5</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32290754</ArticleId><ArticleId IdType="doi">10.2217/imt-2020-0077</ArticleId><ArticleId IdType="pmc">PMC7161588</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Liban</li></country></list><tree><country name="Liban"><noRegion><name sortKey="Kattan, Joseph" sort="Kattan, Joseph" uniqKey="Kattan J" first="Joseph" last="Kattan">Joseph Kattan</name></noRegion><name sortKey="Assi, Tarek" sort="Assi, Tarek" uniqKey="Assi T" first="Tarek" last="Assi">Tarek Assi</name><name sortKey="Kattan, Clarisse" sort="Kattan, Clarisse" uniqKey="Kattan C" first="Clarisse" last="Kattan">Clarisse Kattan</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001118 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001118 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32290754
|texte= Do checkpoint inhibitors compromise the cancer patients' immunity and increase the vulnerability to COVID-19 infection?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32290754" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidFranceV1
| This area was generated with Dilib version V0.6.37. |  |